细胞代谢的重编程现在是肿瘤发生的标志。近年来，胰腺神经内分泌肿瘤（pNET）的研究主要集中在遗传和表观遗传修饰以及相关信号通路上，但很少有研究致力于表征这些肿瘤的代谢特征。在这篇综述中，我们通过分析文献中可用的转录组学和代谢组学数据，彻底研究了 pNET 中的代谢途径。我们从所有公开可用的基因集富集（GSE43797、GSE73338 和 GSE117851）中检索并下载了基因表达谱，以比较差异基于阶段和 MEN1 突变状态的表达基因。此外，我们对 NET 中的代谢组学数据进行了系统回顾。通过结合转录组学和代谢组学方法，我们发现与没有 pNET 的对照相比，pNET 中的独特代谢。我们的分析表明，一碳、谷胱甘肽和多胺代谢、脂肪酸生物合成和支链氨基酸分解代谢存在失调，这些代谢提供了三羧酸循环。这些靶标与 pNET 细胞增殖和转移有关，也可能产生预后影响。在分析有或没有转移、有或没有 MEN1 突变的患者资料时，由于现有研究中发表的临床数据稀缺，我们只观察到一些差异。因此，现在需要进一步的研究来验证我们的数据并研究这些潜在靶标作为生物标志物或治疗解决方案，特别关注 pNET。版权所有 © 2023 Jannin、Dessein、Do Cao、Vantyghem、Chevalier、Van Seuningen、Jonckheere 和 Coppin。

Reprogramming of cellular metabolism is now a hallmark of tumorigenesis. In recent years, research on pancreatic neuroendocrine tumors (pNETs) has focused on genetic and epigenetic modifications and related signaling pathways, but few studies have been devoted to characterizing the metabolic profile of these tumors. In this review, we thoroughly investigate the metabolic pathways in pNETs by analyzing the transcriptomic and metabolomic data available in the literature.We retrieved and downloaded gene expression profiles from all publicly available gene set enrichments (GSE43797, GSE73338, and GSE117851) to compare the differences in expressed genes based on both the stage and MEN1 mutational status. In addition, we conducted a systematic review of metabolomic data in NETs.By combining transcriptomic and metabolomic approaches, we have identified a distinctive metabolism in pNETs compared with controls without pNETs. Our analysis showed dysregulations in the one-carbon, glutathione, and polyamine metabolisms, fatty acid biosynthesis, and branched-chain amino acid catabolism, which supply the tricarboxylic acid cycle. These targets are implicated in pNET cell proliferation and metastasis and could also have a prognostic impact. When analyzing the profiles of patients with or without metastasis, or with or without MEN1 mutation, we observed only a few differences due to the scarcity of published clinical data in the existing research. Consequently, further studies are now necessary to validate our data and investigate these potential targets as biomarkers or therapeutic solutions, with a specific focus on pNETs.Copyright © 2023 Jannin, Dessein, Do Cao, Vantyghem, Chevalier, Van Seuningen, Jonckheere and Coppin.